(Q34184837)

English

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Andrea Marcellusi

object named as

Andrea Marcellusi

11

0 references

Antonio Uccelli

object named as

Antonio Uccelli

8

0 references

Alessandra Lugaresi

object named as

Alessandra Lugaresi

1

0 references

object named as

Diego Centonze

7

0 references

author name string

Ciro Florio

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Vincenzo Brescia-Morra

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Salvatore Cottone

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Paolo Bellantonio

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Marinella Clerico

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Maria di Ioia

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Giovanna De Luca

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Andrea Paolillo

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

BRIDGE study group

13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

5 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Methods for evaluation of medication adherence and persistence using automated databases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Estimating medication persistency using administrative claims data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

5 July 2018

Factors that influence adherence with disease-modifying therapy in MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Patient satisfaction with an injection device for multiple sclerosis treatment.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3368780

28 October 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-7

21 January 2018

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22390218

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2377-12-7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34184837&oldid=2196360283"